ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.210,48
0,58%
S&P 500
5.187,70
0,13%
US Dollar vs BRL
5,0747
0,00%
Bitcoin
62.296,65
-0,06%
Brent Oil
82,03
-1,01%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Akari Therapeutics PLC (AKTX)

  7. Akari Therapeutics PLC (AKTX) Notícias

AKTX

Akari Therapeutics (AKTX)

Akari Therapeutics PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AKTX
DataHoraFonteTítuloCódigoCompanhia
07/05/202418:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
15/03/202413:53PR Newswire (US)Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law FirmNASDAQ:AKTXAkari Therapeutics PLC
11/03/202418:25Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
09/01/202419:25Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
04/01/202414:34Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
02/01/202422:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
01/12/202310:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202317:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
20/10/202317:29Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202317:23Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:AKTXAkari Therapeutics PLC
12/10/202317:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKTXAkari Therapeutics PLC
07/06/202307:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AKTXAkari Therapeutics PLC
06/06/202310:00Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AKTXAkari Therapeutics PLC
31/05/202318:08Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AKTXAkari Therapeutics PLC
16/05/202317:05GlobeNewswire Inc.Aspira Women’s Health Names Torsten Hombeck as Chief Financial OfficerNASDAQ:AKTXAkari Therapeutics PLC
14/04/202317:07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:AKTXAkari Therapeutics PLC
14/02/202318:14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AKTXAkari Therapeutics PLC
09/11/202218:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:AKTXAkari Therapeutics PLC
04/11/202218:01Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:AKTXAkari Therapeutics PLC
12/10/202217:32Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:AKTXAkari Therapeutics PLC
14/09/202213:20Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AKTXAkari Therapeutics PLC
13/06/202208:00GlobeNewswire Inc.Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth StrategiesNASDAQ:AKTXAkari Therapeutics PLC
19/05/202217:05GlobeNewswire Inc.Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual MeetingNASDAQ:AKTXAkari Therapeutics PLC
16/05/202207:43Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:AKTXAkari Therapeutics PLC
16/05/202207:00GlobeNewswire Inc.Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical ProgressNASDAQ:AKTXAkari Therapeutics PLC
11/05/202208:00GlobeNewswire Inc.Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual MeetingNASDAQ:AKTXAkari Therapeutics PLC
10/05/202208:00GlobeNewswire Inc.Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA DermatologyNASDAQ:AKTXAkari Therapeutics PLC
09/05/202208:00GlobeNewswire Inc.Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)NASDAQ:AKTXAkari Therapeutics PLC
29/04/202218:11Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:AKTXAkari Therapeutics PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:AKTX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
ETER3
ETERNIT ON
BOV
AZEV4
AZEVEDO PN
BOV
VVEO3
CM Hospitalar ON
BOV
CRFB3
CARREFOUR ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados